Artelo Biosciences
ARTL
3 hedge funds and large institutions have $37.2K invested in Artelo Biosciences in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, reducing their positions, and 0 closing their positions.
2,556% more capital inflows, than outflows
Capital inflows: $239 | Capital outflows: $9
50% more funds holding
Funds holding: 2 → 3 (+1)
0% less ownership
Funds ownership: 0.77% → 0.77% (-0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$239 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Osaic Holdings
Scottsdale,
Arizona
|
-$9 |
ARTL Hedge Fund Activity: Q1 2024 in Review
3 of the 6,966 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q1 2024, worth a combined $37.2K — up 8.3% from $34.3K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new ARTL positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $239. The largest seller was Osaic Holdings, cutting an estimated $9.
- 3 institutional investors held Artelo Biosciences (ARTL) as of Q1 2024, up from 2 in Q4 2023.
- Funds reported $37.2K of Artelo Biosciences stock for Q1 2024, up 8.3% quarter-over-quarter.
- 1 fund opened new Artelo Biosciences positions in Q1 2024 and 0 closed out, a net change of +1 holder.
- The largest Artelo Biosciences buyer in Q1 2024 was UBS Group, an estimated $239 added.
- The largest Artelo Biosciences seller in Q1 2024 was Osaic Holdings, an estimated $9 sold.
Based on aggregated 13F filings for Q1 2024.